Friday, April 10, 2015 6:42:39 PM
Pacific Biosciences of California, Inc. Menlo Park, CA--(Job Description)-----------
Do you want to use your C++ software engineering talent to solve problems of real scientific and medical importance? Are you bored with the idea of simply contributing to yet another social networking site or fixing bugs in some large company’s search engine? Do you have a desire to be part of a company creating cutting edge technology that is uncovering the mysteries of life itself? Do you want to work at a company that uses robots and lasers and nanotechnology to see a single DNA molecule sequence in real-time? Pacific Biosciences is seeking a talented C++ software engineer to build automated test systems, infrastructure code and optimized algorithm implementations, including well designed APIs for a complex system that produces SMRT (Single Molecule, Real Time) sequencing data which addresses a myriad of diverse scientific application areas. The candidate will develop robust, reliable and performant software infrastructure components, documentation and tests that enable our team to rapidly create a diversity of software solutions.
Responsibilities:
• Work in an exciting multi-disciplinary organization of software and hardware engineers, bioinformaticians, chemists, and molecular biologists developing state-of-the-art, single-molecule, genomic analysis systems.
• Design and write automated functional and unit tests and support developers to troubleshoot system issues or assist in system-level integration.
• Create a variety of infrastructure components that will be the foundational software layers used to build advanced analysis software.
• Quickly identify solutions to complex data processing and automation problems for use in production instrument software and internal tools; provide methods or prototypes for concept evaluation.
• Develop, integrate and test analysis pipeline components for deployment in production software; develop optimized implementations to maximize performance and throughput on available hardware.
• Write design and functional specifications as well as test plans for peer review; maintain software development practices adhering to company standards for coding and unit/functional test coverage.
Skills & Requirements
• M.S. in computer science, electrical engineering or in physical science disciplines; candidates with a similar B.S. degree and a high level of relevant experience will also be considered.
• An expert in C++ with at least 5 years of implementation experience on Linux.
• At least 5 years of experience developing reusable components, automated tests, utilizing formal software development processes, employing best practices.
• Experience maintaining software projects under source control with p4, git, svn, or similar.
• Extensive experience with multithreading programming and optimization techniques including SSE/SIMD vector processing instructions is required.
• Experience with the Intel Xeon Phi computing platform is a plus.
• Understanding of FDA compliance regulations a plus.
• Preference is shown to candidates with strong analytical and development skills who demonstrate the capability to bring solutions beyond the prototype stage for deployment in performance-critical production software.
All qualified applicants will receive consideration for employment without regard to race, sex, color, religion, national origin, protected veteran status, or on the basis of disability, gender identity, and sexual orientation.
http://careers.stackoverflow.com/jobs/85051/senior-software-engineer-pacific-biosciences-of
Recent PACB News
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases • PR Newswire (US) • 05/15/2024 01:45:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:33:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:21:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:12:15 PM
- PacBio Announces First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:05:00 PM
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM